Global Anticholinergic Agent 麻豆原创 Research Report 2025

Publication ID:

PB502253468

Publication Date:

February 13, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Anticholinergic Agent was valued at US$ 6431 million in the year 2024 and is projected to reach a revised size of US$ 9231 million by 2031, growing at a CAGR of 5.3% during the forecast period.
An anticholinergic agent is a type of drug that blocks the action of acetylcholine (a neurotransmitter) in the central and peripheral nervous system. Acetylcholine plays a role in transmitting signals in the parasympathetic nervous system, which controls involuntary bodily functions like digestion, salivation, and urination. By inhibiting acetylcholine, anticholinergic agents help manage conditions related to overactive muscles, excessive secretions, or spasms.
North American market for Anticholinergic Agent is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Anticholinergic Agent is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Anticholinergic Agent include AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical, Mylan, Hansoh Pharmaceutical, Hengrui, Joincare Pharmaceutical, Pfizer, AbbVie, Sanofi, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Anticholinergic Agent, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anticholinergic Agent.
The Anticholinergic Agent market size, estimations, and forecasts are provided in terms of sales volume (kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anticholinergic Agent market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anticholinergic Agent manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Mylan
Hansoh Pharmaceutical
Hengrui
Joincare Pharmaceutical
Pfizer
AbbVie
Sanofi
Novartis AG
GlaxoSmithKline
Astellas Pharma Inc
Sun Pharmaceutical
Macleods Pharmaceuticals
Perrigo
Aurobindo Pharma
Segment by Type
Muscarinic Antagonists
Nicotinic Antagonists
Segment by Application
Surgery
Parkinson's Disease
Asthma
Chronic Obstructive Pulmonary Disease
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anticholinergic Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anticholinergic Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Anticholinergic Agent 麻豆原创 Overview
1.1 Product Definition
1.2 Anticholinergic Agent by Type
1.2.1 Global Anticholinergic Agent 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Muscarinic Antagonists
1.2.3 Nicotinic Antagonists
1.3 Anticholinergic Agent by Application
1.3.1 Global Anticholinergic Agent 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Surgery
1.3.3 Parkinson's Disease
1.3.4 Asthma
1.3.5 Chronic Obstructive Pulmonary Disease
1.4 Global Anticholinergic Agent 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Anticholinergic Agent Revenue 2020-2031
1.4.2 Global Anticholinergic Agent Sales 2020-2031
1.4.3 Global Anticholinergic Agent 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Anticholinergic Agent 麻豆原创 Competition by Manufacturers
2.1 Global Anticholinergic Agent Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Anticholinergic Agent Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Anticholinergic Agent Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Anticholinergic Agent, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anticholinergic Agent, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anticholinergic Agent, Product Type & Application
2.7 Global Key Manufacturers of Anticholinergic Agent, Date of Enter into This Industry
2.8 Global Anticholinergic Agent 麻豆原创 Competitive Situation and Trends
2.8.1 Global Anticholinergic Agent 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Anticholinergic Agent Players 麻豆原创 Share by Revenue
2.8.3 Global Anticholinergic Agent Company Type and 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Anticholinergic Agent 麻豆原创 Scenario by Region
3.1 Global Anticholinergic Agent 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Anticholinergic Agent Sales by Region: 2020-2031
3.2.1 Global Anticholinergic Agent Sales by Region: 2020-2025
3.2.2 Global Anticholinergic Agent Sales by Region: 2026-2031
3.3 Global Anticholinergic Agent Revenue by Region: 2020-2031
3.3.1 Global Anticholinergic Agent Revenue by Region: 2020-2025
3.3.2 Global Anticholinergic Agent Revenue by Region: 2026-2031
3.4 North America Anticholinergic Agent 麻豆原创 Facts & Figures by Country
3.4.1 North America Anticholinergic Agent 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Anticholinergic Agent Sales by Country (2020-2031)
3.4.3 North America Anticholinergic Agent Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anticholinergic Agent 麻豆原创 Facts & Figures by Country
3.5.1 Europe Anticholinergic Agent 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Anticholinergic Agent Sales by Country (2020-2031)
3.5.3 Europe Anticholinergic Agent Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anticholinergic Agent 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Anticholinergic Agent 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Anticholinergic Agent Sales by Region (2020-2031)
3.6.3 Asia Pacific Anticholinergic Agent Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anticholinergic Agent 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Anticholinergic Agent 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Anticholinergic Agent Sales by Country (2020-2031)
3.7.3 Latin America Anticholinergic Agent Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Anticholinergic Agent 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Anticholinergic Agent 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Anticholinergic Agent Sales by Country (2020-2031)
3.8.3 Middle East and Africa Anticholinergic Agent Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anticholinergic Agent Sales by Type (2020-2031)
4.1.1 Global Anticholinergic Agent Sales by Type (2020-2025)
4.1.2 Global Anticholinergic Agent Sales by Type (2026-2031)
4.1.3 Global Anticholinergic Agent Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Anticholinergic Agent Revenue by Type (2020-2031)
4.2.1 Global Anticholinergic Agent Revenue by Type (2020-2025)
4.2.2 Global Anticholinergic Agent Revenue by Type (2026-2031)
4.2.3 Global Anticholinergic Agent Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Anticholinergic Agent Price by Type (2020-2031)
5 Segment by Application
5.1 Global Anticholinergic Agent Sales by Application (2020-2031)
5.1.1 Global Anticholinergic Agent Sales by Application (2020-2025)
5.1.2 Global Anticholinergic Agent Sales by Application (2026-2031)
5.1.3 Global Anticholinergic Agent Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Anticholinergic Agent Revenue by Application (2020-2031)
5.2.1 Global Anticholinergic Agent Revenue by Application (2020-2025)
5.2.2 Global Anticholinergic Agent Revenue by Application (2026-2031)
5.2.3 Global Anticholinergic Agent Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Anticholinergic Agent Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AstraZeneca Anticholinergic Agent Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Boehringer Ingelheim
6.2.1 Boehringer Ingelheim Company Information
6.2.2 Boehringer Ingelheim Description and Business Overview
6.2.3 Boehringer Ingelheim Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Boehringer Ingelheim Anticholinergic Agent Product Portfolio
6.2.5 Boehringer Ingelheim Recent Developments/Updates
6.3 Teva Pharmaceutical
6.3.1 Teva Pharmaceutical Company Information
6.3.2 Teva Pharmaceutical Description and Business Overview
6.3.3 Teva Pharmaceutical Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Teva Pharmaceutical Anticholinergic Agent Product Portfolio
6.3.5 Teva Pharmaceutical Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Company Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Mylan Anticholinergic Agent Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Hansoh Pharmaceutical
6.5.1 Hansoh Pharmaceutical Company Information
6.5.2 Hansoh Pharmaceutical Description and Business Overview
6.5.3 Hansoh Pharmaceutical Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Hansoh Pharmaceutical Anticholinergic Agent Product Portfolio
6.5.5 Hansoh Pharmaceutical Recent Developments/Updates
6.6 Hengrui
6.6.1 Hengrui Company Information
6.6.2 Hengrui Description and Business Overview
6.6.3 Hengrui Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Hengrui Anticholinergic Agent Product Portfolio
6.6.5 Hengrui Recent Developments/Updates
6.7 Joincare Pharmaceutical
6.7.1 Joincare Pharmaceutical Company Information
6.7.2 Joincare Pharmaceutical Description and Business Overview
6.7.3 Joincare Pharmaceutical Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Joincare Pharmaceutical Anticholinergic Agent Product Portfolio
6.7.5 Joincare Pharmaceutical Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Company Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Pfizer Anticholinergic Agent Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 AbbVie
6.9.1 AbbVie Company Information
6.9.2 AbbVie Description and Business Overview
6.9.3 AbbVie Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.9.4 AbbVie Anticholinergic Agent Product Portfolio
6.9.5 AbbVie Recent Developments/Updates
6.10 Sanofi
6.10.1 Sanofi Company Information
6.10.2 Sanofi Description and Business Overview
6.10.3 Sanofi Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Sanofi Anticholinergic Agent Product Portfolio
6.10.5 Sanofi Recent Developments/Updates
6.11 Novartis AG
6.11.1 Novartis AG Company Information
6.11.2 Novartis AG Description and Business Overview
6.11.3 Novartis AG Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Novartis AG Anticholinergic Agent Product Portfolio
6.11.5 Novartis AG Recent Developments/Updates
6.12 GlaxoSmithKline
6.12.1 GlaxoSmithKline Company Information
6.12.2 GlaxoSmithKline Description and Business Overview
6.12.3 GlaxoSmithKline Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.12.4 GlaxoSmithKline Anticholinergic Agent Product Portfolio
6.12.5 GlaxoSmithKline Recent Developments/Updates
6.13 Astellas Pharma Inc
6.13.1 Astellas Pharma Inc Company Information
6.13.2 Astellas Pharma Inc Description and Business Overview
6.13.3 Astellas Pharma Inc Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Astellas Pharma Inc Anticholinergic Agent Product Portfolio
6.13.5 Astellas Pharma Inc Recent Developments/Updates
6.14 Sun Pharmaceutical
6.14.1 Sun Pharmaceutical Company Information
6.14.2 Sun Pharmaceutical Description and Business Overview
6.14.3 Sun Pharmaceutical Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Sun Pharmaceutical Anticholinergic Agent Product Portfolio
6.14.5 Sun Pharmaceutical Recent Developments/Updates
6.15 Macleods Pharmaceuticals
6.15.1 Macleods Pharmaceuticals Company Information
6.15.2 Macleods Pharmaceuticals Description and Business Overview
6.15.3 Macleods Pharmaceuticals Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Macleods Pharmaceuticals Anticholinergic Agent Product Portfolio
6.15.5 Macleods Pharmaceuticals Recent Developments/Updates
6.16 Perrigo
6.16.1 Perrigo Company Information
6.16.2 Perrigo Description and Business Overview
6.16.3 Perrigo Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Perrigo Anticholinergic Agent Product Portfolio
6.16.5 Perrigo Recent Developments/Updates
6.17 Aurobindo Pharma
6.17.1 Aurobindo Pharma Company Information
6.17.2 Aurobindo Pharma Description and Business Overview
6.17.3 Aurobindo Pharma Anticholinergic Agent Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Aurobindo Pharma Anticholinergic Agent Product Portfolio
6.17.5 Aurobindo Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anticholinergic Agent Industry Chain Analysis
7.2 Anticholinergic Agent Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anticholinergic Agent Production Mode & Process Analysis
7.4 Anticholinergic Agent Sales and 麻豆原创ing
7.4.1 Anticholinergic Agent Sales Channels
7.4.2 Anticholinergic Agent Distributors
7.5 Anticholinergic Agent Customer Analysis
8 Anticholinergic Agent 麻豆原创 Dynamics
8.1 Anticholinergic Agent Industry Trends
8.2 Anticholinergic Agent 麻豆原创 Drivers
8.3 Anticholinergic Agent 麻豆原创 Challenges
8.4 Anticholinergic Agent 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Mylan
Hansoh Pharmaceutical
Hengrui
Joincare Pharmaceutical
Pfizer
AbbVie
Sanofi
Novartis AG
GlaxoSmithKline
Astellas Pharma Inc
Sun Pharmaceutical
Macleods Pharmaceuticals
Perrigo
Aurobindo Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.